Author name: Leonardo Arias

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set by Amgen’s B cell depleter Uplizna, approved by the FDA for IgG4-related disease last April.

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently published complete response letter, the agency detailed its reasoning behind the rejection.

OncoNano’s platform, called ON-BOARD, packages drugs in pH-sensitive micelles that ensure their specific delivery near tumors, while also preventing systemic exposure.

  Con el reciente aumento de Bitcoin hasta los $92,000, el mercado de criptomonedas se perfila para un potencial explosivo de ganancias. Sin embargo, la fuerte volatilidad que experimentó el mercado de criptomonedas en el cuarto trimestre de 2025 ha disuadido a muchos inversores, difi …

After a strong open to the year, the public markets suffered a six-month drought that led to biotech’s tightest IPO window in years.

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, global consistency and broader patient access to CAR T therapies.

Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.

In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer meetings than usual and agreed with its advisors only 57% of the time, Jefferies reported.

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.

States received an average of $200 million to expand rural care access. Texas received the most money, while New Jersey received the least.